Skip to content

Randomized controlled clinical trial of Yupingfeng granule in the treatment of allergic rhinitis

Randomized controlled clinical trial of Yupingfeng granule in the treatment of allergic rhinitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014378
Enrollment
Unknown
Registered
2018-01-09
Start date
2018-01-01
Completion date
Unknown
Last updated
2018-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis

Interventions

Yupingfeng Granules:Yupingfeng Granules, 1#, TID, PO, for 1 month
Minzhilin:Minzhilin, 1#, QN, PO, for 1 month
Yupingfeng Granules combined with Minzhilin:Yupingfeng Granules, 1#, TID+Minzhilin, 1#, QN, for 1 month

Sponsors

Jiangsu Province Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. meet the diagnostic criteria of allergic rhinitis; 2. Between 12 and 60 years of age; 3. The onset time in 1 week; 4. Informed consent, volunteer.

Exclusion criteria

Exclusion criteria: 1. Vasomotor rhinitis, eosinophilic rhinitis, allergic sinusitis, acute rhinitis; 2. Merge nasal polyps, nasal septum deviation and other nasal organic changes; 3. Use antihistamines, hormones, anti-leukotriene and other treatment of allergic rhinitis Within 1 month; 4. Pregnancy, lactating women; 5. ECG examination showed prolonged Q-T interval, or patients with severe arrhythmia; 6. Serious primary heart, liver, lung, kidney, blood, or serious illness that affects its survival; 7. Persons who do not have full informed consent due to mental or behavioral disorders; 8. At the investigator's discretion, other conditions that have the potential to reduce enrollment or complicate enrollment, such as frequent changes in the working environment, can result in lost follow-up; 9. Yuping wind particles or dish governance Lin allergies; 10. Patients who are participating in other drug clinical trials.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale/Score, Trichotomy;

Secondary

MeasureTime frame
tIgE, sIgE;FeNO, NNO;Nasal resistance, sound, breathing;

Countries

China

Contacts

Public ContactLei Cheng

Jiangsu Province Hospital

jspent@126.com+86 13776620807

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026